AliveCor is a Mountain View, California-based provider of FDA-cleared personal electrocardiogram (ECG) technology solutions led by CEO Priya Abani. Its core consumer hardware includes the clinically validated KardiaMobile device and the multi-lead KardiaMobile 6L, which detects atrial fibrillation, bradycardia, tachycardia and various ECG rhythms. The company offers the Kardia AI-enabled platform to assist patients and clinicians in the efficient detection of atrial fibrillation. For enterprise customers AliveCor provides an enterprise platform including KardiaComplete for payors, employers, and health systems enabling front-end and back-end integration. AliveCor also operates a digital health subscription, KardiaCare, with more than 130,000 members offering advanced features to understand and manage heart health. The company intends to use new funding to expand its development efforts. AliveCor, based in Mountain View, CA and led by CEO Priya Abani, develops AI-based personal ECG technology and enterprise cardiology solutions. Its FDA-cleared KardiaMobile device is a clinically validated personal ECG that provides instant detection of atrial fibrillation, bradycardia, tachycardia, and normal heart rhythm. The company’s enterprise platform enables third-party providers to manage patients’ heart conditions with front-end and back-end integration to AliveCor technologies. To date, AliveCor’s products have served more than one million customers and recorded over 85 million ECGs. The company says it will use recent funding to accelerate growth of its remote cardiology platform domestically and around the world. Kardia aids patients and clinicians in the early detection of atrial fibrillation, a common arrhythmia associated with elevated stroke risk. AliveCor develops single- and six-lead smartphone ECG devices and AI-based interpretation software for consumer and point-of-care use. Its latest hardware, KardiaMobile 6L, launched in June and captures six perspectives by adding a third contact point. The company also secured FDA clearance for KardiaAI, an update for KardiaMobile and KardiaStation. AliveCor recently disclosed a new $5.78M infusion of capital and has a prior $30M round from 2017 led by Mayo Clinic and Omron Healthcare. Management has not announced how the new funds will be allocated. The business faces competition from entrants such as the Apple Watch’s ECG feature and has previously discontinued its KardiaBand for Apple Watch. AliveCor develops AI-enabled solutions to improve cardiac care, notably KardiaMobile and KardiaBand. KardiaMobile is an FDA-cleared product that instantly detects atrial fibrillation and normal sinus rhythm and is used worldwide for accurate ECG recordings. Paired with the Kardia app, KardiaMobile and KardiaBand provide instant analysis for detecting atrial fibrillation and normal sinus rhythm. Kardia is an AI-enabled platform for clinicians to manage patients for early detection of atrial fibrillation. The company said it will use new capital to support growth as well as research and development efforts. AliveCor is a Mountain View, California-based provider of FDA-cleared mobile electrocardiogram technology. Led by CEO Vic Gundotra, the company has launched Kardia Pro, an artificial intelligence-enabled platform that helps doctors monitor patients for early detection of atrial fibrillation. Kardia Pro tracks physiology measures such as weight, activity and blood pressure and creates a personal heart profile for each user, enabling user identification. AliveCor raised $30M in a Series D funding round led by Omron Healthcare, with participation from Mayo Clinic and existing inside investors. The company will use the capital to accelerate innovations in heart health and to continue expansion of the business. Its technology focuses on early detection of atrial fibrillation, the most common cardiac arrhythmia that increases stroke risk.

Total raised

$134M

Funding rounds

7

Latest round

Series E

Latest activity

Nov 2020